Think pharma ads have too many celebrities and jingles? Not many actually use them, study findsnews2023-12-08T18:15:40+00:00December 8th, 2023|Endpoints News|
Roche touts full data for drug in first-line PIK3CA-mutated breast cancernews2023-12-08T17:01:01+00:00December 8th, 2023|Endpoints News|
Gavi announces $1.8B for vaccine access, pandemic preparedness efforts in Africanews2023-12-08T16:58:04+00:00December 8th, 2023|Endpoints News|
How one lab’s decadeslong search for the ‘holy grail’ of sickle cell led to the first CRISPR therapynews2023-12-08T16:39:55+00:00December 8th, 2023|Endpoints News|
FDA approves two gene therapies for sickle cell disease, including first that uses CRISPRnews2023-12-08T16:34:23+00:00December 8th, 2023|Endpoints News|
Novartis preps Kisqali for FDA; Ventyx cuts 20% of workers; Keytruda plus Lenvima hits PhIII setbacknews2023-12-08T15:52:20+00:00December 8th, 2023|Endpoints News|
Bristol Myers’ lead deal negotiator to depart after inking series of multibillion-dollar acquisitionsnews2023-12-08T15:22:09+00:00December 8th, 2023|Endpoints News|
The Endpoints 100 survey: Has biotech hit rock bottom?news2023-12-08T12:16:12+00:00December 8th, 2023|Endpoints News|
Spyre Therapeutics raises $180M in private placement, pushing cash runway into second half of 2026news2023-12-08T12:12:58+00:00December 8th, 2023|Endpoints News|
Graphite Bio divests gene editing pipeline to newly-formed Kamau Therapeutics after announcing reverse merger with Lenznews2023-12-08T11:29:04+00:00December 8th, 2023|Endpoints News|
